Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Lawmakers Eye Genomic Medicine Bill to Fuel Diagnostics Development
May 31, 2016
- AMED to Support Drug Discovery Research Using Existing Drugs as “Tool Compounds”
May 31, 2016
- G7 Leaders Vow to Consider New Incentives to Spur AMR R&D
May 30, 2016
- MHLW Panel OKs Sanofi’s PCSK9 Inhibitor on Equal Footing with Repatha
May 30, 2016
- AZ’s Ticagrelor, Boehringer’s Triple Combo Fail to Clear MHLW Advisory Panel
May 30, 2016
- AMED to Allocate 820 Million Yen for Measures against Antimicrobial Resistance
May 27, 2016
- Clinical Research Bill Unlikely to Clear Diet in Current Session
May 27, 2016
- MHLW to Request Budgets to Promote Venture Companies in Response to Growth Strategy
May 26, 2016
- Pemphigoid Added to List of Clinically Significant Adverse Reactions for DPP-4 Inhibitors: Safety Bulletin
May 26, 2016
- MHLW Working Group Urges Govt to Push NTD Drug Development at Mie Summit
May 25, 2016
- MHLW to Begin Discussions this Fiscal Year on Regulation of Plasma Exports
May 25, 2016
- AZ’s Ticagrelor, Boehringer’s Triple Combo Added to MHLW Panel’s Review Agenda for May 27
May 24, 2016
- Takecab-Contained Blister Packs for H. pylori Eradication, Other Products to Join NHI Price List on May 25
May 24, 2016
- MHLW OKs Add’l Indications for Avastin, Other Drugs
May 24, 2016
- MHLW’s Expanded Development Request Scheme Gets Underway
May 23, 2016
- Lecture Fees Paid “Purely as Compensation” Would Not Be Subject to Regulation under New Clinical Research Bill: Health Policy Bureau Chief
May 23, 2016
- Govt’s Draft Economic Growth Strategy Embraces Use of Big Data by PMDA
May 20, 2016
- Deregulation Panel Calls for Revisiting Plasma Export Restrictions, Wants Conclusion by FY2018
May 20, 2016
- Clinical Research Bill to Make It Easier for Companies to Provide Unapproved Drugs for Clinical Programs: LDP Lawmaker
May 20, 2016
- Council Determines Parathyroid Hormone Preparation for Hypoparathyroidism Has High Unmet Medical Need
May 20, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…